



To: INVO Bioscience Investors

From: Kathleen Karloff

Subject: Investor Update

Date: December 10, 2009

INVO Bioscience would like to update its investors on the activities of 2009 and the plan to expand during 2010.

Financing: Much focus in 2009 was put on raising capital. In these economic times, investors in early stage companies have become few, even in companies that are beginning to sell their products. The lack of funding during most of 2009 caused difficulty for INVO to meet its goals. Our first responsibility to assure compliance & protect our shareholders investments was to maintain our filings as in our 8K's, 10Q's and now the S-1 to remain in good standing as a public company with the SEC. Our second responsibility was to increase investor value through sales and training. Most of the funds have been allocated to sales, seminars, operations and physician training. In addition, all of the current employees (4.5) have assisted INVO Bioscience in its funding requirements by deferring their salaries as of March of 2009. Salaries will be re-instated as funding allows.

In July of 2009 INVO signed an agreement for a bridge private placement / equity securities financing for \$500,000. The terms can be found in the 8K filed in July 17, 2009. The IVOB stock was trading in, or about 10 cents at the time and this determined the terms of the financing. This financing closed in September and details can be found in the 8K filed on September 16, 2009

On October 28, 2009 INVO Bioscience signed an agreement with AGS capital for a Reserve Equity Financing for up to \$10,000,000 over a period of two years, details can be found in the 8K filed on November 3, 2009. INVO is required to file a S-1 prior to receiving the first capital from the Reserve Equity Financing. The S-1 is anticipated to be filed before December 15, 2009 and then it can take from 2 weeks or up to 2 months for the SEC to accept the S-1. INVO has the ability to request the first capital on the day the S-1 is accepted by the SEC.

Many different forms of financing were evaluated during the process and the financing chosen was deemed the least dilutive for the INVO stock holders.

Sales and distribution: Many distribution agreements have been signed in 2009. Some countries under these distributors have started to sell the INVOcell and many have additional registration requirements along with requiring the CE Mark. Also many countries want to, and are doing initial cases to obtain country specific data and to validate their training prior to launching country wide. Below is a summary of Current distribution agreements.

Distributor	Sales started	Notes
*Galaxy IVF	Pakistan	Embryologist recently added to train physicians. Registration ongoing in Egypt.
Daxley Group	Columbia, Venezuela	Registrations ongoing Ecuador, Panama, Argentina, Uruguay, Chile, Brazil
Nacer	Peru	Peru
CER	Guatemala	Guatemala
Gonagen	Turkey	Getting in region data prior to full launch in other countries
Progressive Group	None	China, Hong Kong and Taiwan started lengthy registrations
ENVI Med	None	Thailand started lengthy registrations
Meditech 1st	None	Canada, approved, starting 1 st Qtr

* Obtained first birth from an INVOcell commercial product.

Other countries doing procedures that do not currently have a distribution network (ship direct):

In Africa: Togo, Cameroon, Benin

In Europe: Spain, Austria.

Operations: Many Milestones were met in 2009. The most major has been INVO Bioscience announcing the birth of the first baby through commercially sold INVO devices, having an ongoing 36% pregnancy rate in South America, as well as acquiring funding which is guaranteed for the next 2 years.

Training: Dr Ranoux has traveled extensively over 2009 to train physicians and distributors, hold workshops, and participate in conferences. Dr. Ranoux has had training, information workshops, interviews and articles, and lectures in Columbia, Peru, Venezuela, Argentina, Guatemala, Togo, Austria, Turkey, Pakistan and India.

Conferences Attended by INVO Bioscience: European Society of Reproduction and Embryology, the American Society of Reproductive Medicine, The Middle Eastern Fertility Society, The Latin America Reproductive Association, The First Congress of GIERAF in Africa. Dr Ranoux was invited to speak on the INVO technology at many of these meetings. The purpose of attending the conferences is to inform as many physicians about the INVO procedure in the countries we are selling in or will be selling to in the near future.

Currently in Progress: INVO Bioscience has been working aggressively to expand the reach of INVO with the resources currently available to us. Negotiations take time and distributors want to do market research and some local data prior to signing an agreement. The countries currently under negotiation:

Countries	Status	Notes
South Africa	Training Scheduled	Registered
India	Training Scheduled	Registered
Greece	Training TBD	Registered
Russia	Training TBD	Distributor started registration
Bulgaria	Negotiating	
Cyprus	Negotiating	
Italy	Negotiating	Registering

*INVO Bioscience has several interested companies that are negotiating and doing due diligence for Europe and other regions. NOTE: Countries currently under registration will need to be developed in 2010.

Looking Forward to 2010: INVO Bioscience is very excited and enthusiastic about moving into 2010. With funding becoming more available and sales revenue beginning to rise we will have additional resources to penetrate the markets that we are currently registering in and finalizing distribution agreements with. Latin America will expand the most rapidly due to our foothold currently being the strongest in that region. INVO has three distributors operating in South America and our pregnancy rates are excellent in the region. Galaxy IVF in the Middle East will continue adding INVO centers in Pakistan and are planning on expanding to Egypt and Saudi Arabia.

The addition of India will be exciting. India has a population of 1.15 Billion people with an estimated 14 million infertile couples. India has power infrastructure issues throughout most of the country therefore traditional IVF is not widely available and unreliable to support. INVO's lack of reliance on electric power will make infertility treatment an option that most of the population does not currently have.

Russia is losing approximately 7% of their population and has one of the highest infertility rates in the world. The Russian government is giving incentives to couple to have children and is looking for a low cost infertility treatment. Registration with our potential distributor has been started.

FDA: INVO Bioscience is planning on starting the process of FDA clearance in 2010. The product development, testing, and pre clinical work required to support the 510 (k) is complete and we have an open IDE to start a clinical study to support the 510 (k). The clinical study is costly and will not be started until INVO is confident that allocating the resources for the study will not interrupt support of sales in other parts of the world. We are confident that this will happen in 2010 and allow for a 2011 clearance.

Revenue: Revenue figures originally projected by INVO for 2009 were created assuming that appropriate funds would be available. INVO Bioscience spent most of 2009 with our attention geared toward acquiring this funding. With this said, 2010's forecast is below. It is a range based off the distribution we currently have in place:

Q1	Q2	Q3	Q4	Year
\$21,150	\$74,025	\$139,975	\$197,850	\$433,000
\$33,550	\$117,425	\$218,075	\$301,950	\$671,000

Please contact me if you have any specific questions.

Sincerely,

Kathleen Karloff

Katiekarloff@invobioscience.com